Is It Time To Reconsider Alphatec Holdings (ATEC) After Its Sharp Share Price Slide

• If you are wondering whether Alphatec Holdings at around US$11 is a bargain or a value trap, the key is to look past the headline share price and into how it stacks up on valuation.
• The stock has seen a 9.5% decline over the last week, a 19.2% decline over the last 30 days, and is down 47.0% year to date, even though the 1 year return sits at 8.5%.
• These moves sit against a backdrop of ongoing interest in medical equipment companies, with investors weighing up growth potential in specialist devices against volatility in share prices. For Alphatec Holdings, that mix of potential and risk has kept valuation in focus as prices have shifted over the past year.
• On Simply Wall St's valuation framework, Alphatec Holdings currently records a value score of 6 out of 6. The rest of this article will break down how different valuation approaches reach that result and outline a more complete way to think about value at the end.

Alphatec Holdings delivered 8.5% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Approach 1: Alphatec Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows and then discounts them back to today to estimate what the business might be worth in total right now.

For Alphatec Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is a loss of $49.26 million, so the starting point is negative. The model then uses analyst estimates and further extrapolations from Simply Wall St to build out the future path.

Analysts provide explicit free cash flow estimates up to 2030, including a projected $179.10 million in 2030. Beyond those published forecasts, additional annual projections out to 2035 are extrapolated to complete the second stage of the model.

Discounting all those projected cash flows back to today produces an estimated intrinsic value of about $24.92 per share. Compared with a recent share price around $11, this indicates the stock is 55.9% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Alphatec Holdings is undervalued by 55.9%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Alphatec Holdings.

Approach 2: Alphatec Holdings Price vs Sales

For companies where profits are limited or volatile, investors often look at revenue based metrics, which is why the P/S ratio is a useful way to think about value. It compares what you pay per share with the sales the business is already generating, so it is less affected by accounting items that can move earnings around.

Growth expectations and risk still matter. Higher expected sales growth or more resilient revenue can justify a higher P/S multiple, while greater uncertainty or thinner margins tend to point to a lower, more conservative multiple.

Alphatec Holdings currently trades on a P/S of 2.18x. That sits below the Medical Equipment industry average P/S of 2.66x and below the peer group average of 3.82x. Simply Wall St’s Fair Ratio framework estimates that, given factors such as Alphatec’s growth profile, industry, profit margins, market cap and risk characteristics, a “normal” P/S for the company would be around 3.28x.

Because the Fair Ratio reflects company specific traits rather than just broad group averages, it can give a more tailored view than a simple comparison with peers or the wider industry.

Based on a P/S of 2.18x compared with a Fair Ratio of 3.28x, Alphatec Holdings appears undervalued on this measure.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Alphatec Holdings Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take that next step by letting you attach a clear story about Alphatec Holdings to your own assumptions for future revenue, earnings, margins and a fair value, then compare that fair value with the current price to decide whether the stock looks attractive or stretched. This all happens within Simply Wall St's Community page, where Narratives are updated automatically when new earnings or news arrive. For example, one investor might build a bullish Alphatec Holdings Narrative around a fair value of about US$28.00 per share with higher profit margins and a future P/E of about 24.4x. Another might lean on a more cautious Narrative closer to US$22.00 per share with a different growth and margin outlook. A third might align with a consensus style view around US$24.62 per share. This gives you a clear way to choose the story that best matches your expectations.

Do you think there's more to the story for Alphatec Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com